SCHEMBL971858

SCHEMBL971858

COc1c(C(=O)NN2CCOCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.67
CNR1 P21554 13/20 0.64
CYP2C9 P11712 2/20 0.64
GPR55 Q9Y2T6 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2D6 P10635 1/20 0.64
MAPT P10636 1/20 0.64
ALOX15 P16050 1/20 0.64
CYP2C19 P33261 1/20 0.64
KMT2A Q03164 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
ABCC4 O15439 1/20 0.55
MLNR O43193 1/20 0.55
ABCB11 O95342 1/20 0.55
CHRM2 P08172 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970687 0.93 CNR2 (0.57) CNR2CNR1CYP2C9GPR55KDM4E
SCHEMBL974370 0.92 CNR2 (0.78) CNR2CNR1CYP2C9GPR55KDM4E
SCHEMBL969992 0.90 CNR1 (0.60) CNR2CNR1CYP2C9GPR55KDM4E
SCHEMBL971988 0.89 CNR1 (0.57) CNR2CNR1CYP2C9GPR55CYP1A2
SCHEMBL973809 0.87 CNR2 (0.68) CNR2CNR1CYP2C9GPR55KDM4E
SCHEMBL970602 0.84 CNR1 (0.72) CNR2CNR1CYP2C9GPR55KDM4E
SCHEMBL972417 0.83 CNR1 (0.77) CNR2CNR1CYP2C9GPR55CYP1A2
SCHEMBL28084167 0.82 CNR1 (0.62) CNR2CNR1CYP2C9GPR55CYP1A2
SCHEMBL971377 0.82 CNR1 (0.57) CNR2CNR1CYP2C9GPR55ABCC4
SCHEMBL970896 0.82 CNR1 (0.64) CNR2CNR1CYP2C9GPR55ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872006-B2 Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-01-18 US claimed
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-02-19 US claimed
US-7872006-B2 Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-01-18 US disclosed
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-02-19 US disclosed
EP-1951678-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-06 EP disclosed
WO-2007046550-A1 PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048256-A1 Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity CNR1, CNR2, OPRD1 CNR2 2/4885CNR1 1/4885CYP2C9 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.